ESR1 and breast carcinoma: Gene signatures that include the 70-gene signature[8], 21-gene recurrence score (commercially developed as Oncotype Dx)[9], PI3K signature[10], core serum response signature (CSR)[11], and the grade signature[12], have been developed to predict the survival of breast cancer patients, and have been used to predict the outcome for ER-positive patients.